Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

Augenheilkunde Up2date is a pivotal journal in the field of ophthalmology, published by GEORG THIEME VERLAG KG, a renowned publisher known for its commitment to advancing medical knowledge. With its ISSN 1616-9719 and E-ISSN 1616-9735, this journal serves as a vital resource for researchers, professionals, and students interested in the latest developments and nuanced discussions in eye health. Although not available as open access, its curated content offers significant insights into contemporary research, clinical practices, and emerging trends in ophthalmology, thus promoting the continuous professional development of its readers. There is an emphasis on providing comprehensive reviews that encapsulate the pertinent advancements in the field, making it an essential publication for those aiming to enhance their expertise in eye care and vision science.

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

CORNEA is a prestigious peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the rapidly advancing field of ophthalmology with a particular emphasis on corneal research and diseases. With an impact factor categorized in the prestigious Q1 quartile for its discipline, CORNEA has established itself as a leading platform for the dissemination of both fundamental and clinical studies since its inception in 1982. The journal is ranked 25th out of 137 in the Scopus Medicine-Ophthalmology category, placing it in the 82nd percentile among its peers, which underscores its vital role in influencing ocular research and clinical practices. While the journal is not currently open access, it provides valuable insights and updates for professionals, researchers, and students working to advance knowledge in corneal health, contributing significantly to the ongoing dialogue in the ophthalmological community. With a commitment to excellence, CORNEA continues to publish high-quality research and reviews in its pursuit to improve ocular outcomes and patient care.

The Journal of the Korean Ophthalmological Society, with ISSN 0378-6471 and E-ISSN 2092-9374, is a pivotal resource in the field of ophthalmology, published by the esteemed Korean Ophthalmological Society. Based in South Korea, this journal is committed to advancing knowledge in ophthalmology through the dissemination of research that spans both clinical and experimental studies. Despite its current Q4 ranking in the 2023 Ophthalmology category, it serves as a crucial platform for emerging scholars, practitioners, and students seeking to contribute to and learn from the latest developments in eye care. While the journal does not currently offer open access, it is dedicated to fostering scientific dialogue and innovation within the community. With convergence years from 2018 to 2024, the journal's focus on contemporary issues in ophthalmology positions it as a relevant and timely source of information, critical for those engaged in this dynamic field. For further inquiries, the journal can be contacted at their address in Seoul, South Korea: SKY 1004 BLDG 701, 50-1 Jungnim-ro, Jung-gu, 04508.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

Ophthalmic Research, with ISSN 0030-3747 and E-ISSN 1423-0259, is a distinguished peer-reviewed journal published by Karger in Switzerland. Established in 1970, this journal serves as a vital resource for exploration and dissemination of knowledge within the fields of Ophthalmology, Cellular and Molecular Neuroscience, and Sensory Systems, maintaining its relevance through its convergence into modern research methodologies leading up to 2024. With impressive rankings in 2023, it holds a Q2 quartile in both Ophthalmology and Medicine (miscellaneous), reflecting its significant contribution to the academic community, alongside Scopus ranks that position it favorably in the competitive landscape of medical and neuroscientific literature. Although not open access, the journal ensures that high-quality research remains accessible to its readership, which includes researchers, professionals, and students eager to stay at the forefront of ophthalmic advancements. By fostering interdisciplinary collaboration and facilitating high-level discourse, Ophthalmic Research is pivotal for those committed to advancing the future of eye care and vision sciences.